Evidence map›Paper›PMID 42321347›Full record

ArticleScientific reports2026

Biomimetic macrophage membrane-coated nanoparticles for targeted cardioprotection against myocardial ischaemia-reperfusion injury.

Hengheng Li, Yanlin Yu, Daiwen Yin, Suxin Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hengheng LiDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yanlin YuDepartment of Nephrology, the Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Army Medical University Xinqiao Hospital, Chongqing, 400037, China.
Daiwen YinThe Sixth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, 100048, China.
Suxin LuoDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. luosuxin@hospital.cqmu.edu.cn.

Funding

Standardized Diagnosis and Treatment of Heart Failure 2025cyjstg006
6 · The paper itself

Abstract

Myocardial ischaemia-reperfusion injury (MIRI) exacerbates cardiomyocyte damage through oxidative stress, inflammation, and apoptosis, limiting the efficacy of reperfusion therapies. We developed PB1-Lip@M-CST, a biomimetic nanoparticle comprising procyanidin B1 (PB1)-loaded liposomes coated with macrophage cell membranes and surface-functionalized with the cardiac-specific targeting peptide CSTSMLKAC (CST). The nanoparticles were characterized for hydrodynamic size, zeta potential, core-shell morphology, retention of macrophage surface proteins (CCR2, CD11b, CD36), high encapsulation efficiency, and sustained drug release. In vitro, PB1-Lip@M-CST markedly reduced phagocytic uptake by RAW 264.7 macrophages, enhanced internalization in HL-1 cardiomyocytes in a CST-dependent manner, and provided superior protection in CoCl

Indexed as

Biomimetic MaterialsCardiotonic AgentsMacrophagesMyocardial Reperfusion InjuryNanoparticlesAnimalsApoptosisBiflavonoidsBiomimeticsCell MembraneLiposomesMaleMiceMyocytes, CardiacOxidative StressPhosphatidylinositol 3-KinasesBiflavonoidsCardiotonic AgentsLiposomesPhosphatidylinositol 3-KinasesProanthocyanidinsProto-Oncogene Proteins c-aktReceptors, CXCR4Biomimetic nanoparticlesCardiac-targeted deliveryMacrophage membrane coatingMyocardial ischaemia-reperfusion injuryProcyanidin B1

Identifiers

PMID42321347
PMCPMC13554186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.